Summary
Galapagos Cell Therapeutics has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €20,503. Its solvency ranks better than 25% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 18-02-2025 Normal situation
- Registered office
- 66 active companies are registered at this address 4 started in the 12 months before. Source: KBO register, as of 4 November 2026.
- Activity
- Research and development on biotechnology NACE 72101and 1 other
- Establishment unit
- 2.370.298.037 2800 Mechelen, since 18-02-2025
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Board and ownership
Board
- Jason TreeseDirector
- Aaron CoxDirector
- Auditor
- BDO Bedrijfsrevisoren
Shareholders
- Lakefront Biotherapeuticsconsolidated· score 97LEI register
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Too few figures to score
Annual accounts 2025
- Gross margin
- -€23,727
- Equity
- €20,503
- Total assets
- €280,466
Turnover not published (abbreviated format)
Signalsraises riskEquity €20,503 (7.3% of total assets)Weak solvency compared with the sectorYoung companylowers riskSector: Scientific research and development (NACE 72)Liquidity: current ratio 1.08, cash €264,463Size: total assets €280,466neutralLatest accounts filed on timeShow the evidence
Bankruptcy probability
No current score
Insufficient figures
A score requires measurable solvency, liquidity and profitability. Missing figures are not a judgement about the company.
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
03-2026: 0.6%
04-2026: 0.6%● unchanged vs 03-2026
05-2026: 0.6%● unchanged vs 04-2026
06-2026: 0.6%● unchanged vs 05-2026highest value
07-2026: 0.1%▼ -0.5 percentage points vs 06-2026lowest value
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Seven signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 25% of 271 sector peers (2025).
NBB · sector comparisonPosition among 271 sector peers
Solvency
better than 25%
← weakest
strongest →
raises risk · Young company
Founded in 2025, a year ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 05-06-2026, 56 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
56 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
Key points
- Caution: Board changedlatest change 27-02-2026 · 2 in office 1 joined · 3 left View
Recent changes
- · Gazette deed Resignation: Robert Hughes (director)Appointment: Aaron Cox (director)
- · Gazette deed 2 directors appointed, 2 directors resigningResignations: Valeria Cnossen (director) and Guy Peeters (director) · Appointments: Jason Treese (director) and Robert Hughes (director)
- · Gazette deed Transfer proposal: Galapagos NV transfers a branch of activity to Galapagos Cell Therapeutics
Comparable companies
These companies have the same main activity as Galapagos Cell Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €201,000 and €489,000, founded between 2024 and 2025.
| Company | Total assets | Gross margin |
|---|---|---|
| Galapagos Cell Therapeutics Mechelen | €280,466 | -€23,727 |
| Conventures Machelen (Brab.) | €246,326 | -€3,674 |
| ELKEDONIA BELGIUM Charleroi | €228,425 | -€55,218 |
| EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM Liège | €305,468 | -€23,069 |
| Hemastatx Charleroi | €200,755 | -€36,090 |
| HEPHAISTOS-BELGIUM Liège | €242,189 | -€98,146 |
| BLUE ARMOR Neupré | €489,312 | -€21,003 |
Key facts about Galapagos Cell Therapeutics
- What is the company number of Galapagos Cell Therapeutics?
- The company number of Galapagos Cell Therapeutics is 1020.101.488. The VAT number is the same number with BE in front: BE 1020.101.488.
- Where is Galapagos Cell Therapeutics based?
- The registered office is at Schaliënhoevedreef 20T, 2800 Mechelen.Company details
- What does Galapagos Cell Therapeutics do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of Galapagos Cell Therapeutics?
- The legal form of Galapagos Cell Therapeutics is Public limited company (NV).
- When was Galapagos Cell Therapeutics founded?
- Galapagos Cell Therapeutics was founded on 18-02-2025.
- Is Galapagos Cell Therapeutics still active?
- Yes, Galapagos Cell Therapeutics is an active enterprise in the KBO register.
- What is the turnover of Galapagos Cell Therapeutics?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.Financials
- Where can I find the annual accounts of Galapagos Cell Therapeutics?
- Galapagos Cell Therapeutics filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.Lakefront Biotherapeutics · 3 companies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.